Located in the Osong 2 Industrial Complex, Optus Pharmaceutical’s Osong Plant 2 is a production base established to expand its ophthalmic solution manufacturing capacity. The plant operates an integrated system that efficiently covers the entire process—from manufacturing to inspection for foreign matter and seal integrity, labeling, and packaging. With an annual production capacity of approximately 360 million units, it represents the largest eye drop production facility in Korea, achieving a total annual capacity of 830 million units when combined with Osong Plant 1.
By maintaining a manufacturing environment that meets global standards, the plant enhances both product quality consistency and production efficiency.
It manufactures and manages products using manufacturing facilities dedicated to a single formulation and storage facilities operated by advanced automation. Based on a thorough contamination control strategy, including monitoring through a Building Management System (BMS), the facility operates an optimized production system that ensures a clean and safe environment free from cross-contamination.
With an annual production capacity of approximately 360 million units, it represents the largest eye drop production facility in Korea, achieving a total annual capacity of 830 million units when combined with Osong Plant 1.
Planning
Annual quality control plan is established using risk management tools
Implementation
Quality control activities (e.g. product testing, validation, calibration) are performed as per the established plan
Evaluation
Comprehensive review of the carried out activities, product quality review, trend analysis, self audit
Improvement
Improvement plans for the part where improvement is considered necessary and implementation of plans.
Copyright 2022. OPTUS Pharmaceutical Co., Ltd. All rights reserved.
